HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Section

Policy

IRA, state PBM reform, Medicare, and regulatory action

Roivant’s CEO thinks China is a ‘red herring’
PolicyFierceBiotech ↗
Roivant’s CEO thinks China is a ‘red herring’
China’s biotech rise has been a persistent concern for federal health leaders, Congress, and many biopharma ex…
Apr 18, 2026
AACR: FDA vet Pazdur bemoans state of agency, warns of political influence and ‘sense of anxiety’
PolicyFierceBiotech ↗
AACR: FDA vet Pazdur bemoans state of agency, warns of political influence and ‘sense of anxiety’
Asked by Fierce if he'd consider returning to the FDA, Pazdur said he wouldn't serve again under the Trump adm…
Apr 18, 2026
Trump Administration Again Blocks UNFPA Funding Under Kemp-Kasten
PolicyBriefing
Trump Administration Again Blocks UNFPA Funding Under Kemp-Kasten
Using the Kemp-Kasten amendment, the administration withheld $32.5 million in FY2025 UNFPA support and is expe…
Apr 17, 2026
Predictive analytics pushes lab data into drug commercialization policy
PolicyBriefing
Predictive analytics pushes lab data into drug commercialization policy
Quest Diagnostics highlights growing pharma use of predictive analytics and lab results to improve launch targ…
Apr 17, 2026
America First MOUs Redefine U.S. Global Health Aid as Co‑Investment Model Takes Hold
Policy
America First MOUs Redefine U.S. Global Health Aid as Co‑Investment Model Takes Hold
The 2026‑2030 America First health agreements push partner nations to replace U.S. funding with domestic spend…
Apr 17, 2026
RFK Jr. Defends FDA Leadership in Heated House Hearing
PolicyBriefing
RFK Jr. Defends FDA Leadership in Heated House Hearing
HHS Secretary Robert F. Kennedy Jr. used his April 16 House testimony to back FDA Commissioner Marty Makary am…
Apr 17, 2026
← Newer Page 14 Older →
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.